Zynerba Pharmaceuticals Inc logo

ZYNE - Zynerba Pharmaceuticals Inc News Story

$4.63 -0.3  -5.9%

Last Trade - 24/02/20

Sector
Healthcare
Size
Small Cap
Market Cap £88.0m
Enterprise Value £28.2m
Revenue £66.3k
Position in Universe 4162nd / 6408

BRIEF-Zynerba Pharmaceuticals Announces Achievement Of Enrollment Target In Phase 2 Trial Of Zygel In Autism Spectrum Disorder

Mon 13th January, 2020 12:37pm
Jan 13 (Reuters) - Zynerba Pharmaceuticals Inc  ZYNE.O :
    * ZYNERBA PHARMACEUTICALS ANNOUNCES ACHIEVEMENT OF
ENROLLMENT
TARGET IN PHASE 2 TRIAL OF ZYGEL™ IN AUTISM SPECTRUM DISORDER
    * ZYNERBA PHARMACEUTICALS - EXPECTS TO ANNOUNCE TOPLINE
RESULTS
FROM PHASE 2 TRIAL OF ZYGEL IN Q2 OF 2020

Source text for Eikon:  ID:nGNX3fBgsT 
Further company coverage:  ZYNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.